Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 276

  • 3 926 clinical trials
  • 1 543 recruiting
  • 706 conditions
  • 31 countries

Conditions in this area

706 conditions with trials, the busiest first

Non-small cell lung cancer332Breast cancer170Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic106Prostate cancer102Colorectal cancer90Ovarian cancer90Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Chronic lymphocytic leukaemia80Malignant melanoma79Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV59Pancreatic carcinoma57Hormone-refractory prostate cancer56Bladder cancer55Gastric cancer55Endometrial cancer53+682

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 926 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 926 clinical trials

Squamous cell carcinoma of skin

Not recruiting

Study of Cemiplimab Compared to Placebo After Surgery and Radiation for Patients with High-Risk Skin Squamous Cell Carcinoma

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Malignant melanoma

Not recruiting

Study on the Effectiveness of Pembrolizumab and Lenvatinib for Patients with Resectable Mucosal Melanoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Institut Gustave Roussy

Breast cancer female

Not recruiting

Study on Infertility Risk from Chemotherapy in Young Breast Cancer Patients Using Follitropin Beta and Follitropin Alfa for Egg/Embryo Preservation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Follitropin Alfa
  • Sponsor:Centre Oscar Lambret

Neoplasm malignant+1

Not recruiting

Study of Entrectinib for Patients with Advanced or Metastatic Solid Tumors with Specific Gene Changes

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Entrectinib
  • Sponsor:F. Hoffmann-La Roche AG

Non-small cell lung cancer metastatic

Not recruiting

Study on the Effectiveness and Safety of Atezolizumab and Drug Combination for Patients with Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Plasma cell myeloma

Not recruiting

Study on the Effectiveness and Safety of Cevostamab and Tocilizumab for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cevostamab
  • Sponsor:F. Hoffmann-La Roche AG

Breast cancer

Not recruiting

Comparison of estriol, prasterone and estriol with lactobacillus for vulvovaginal atrophy in breast cancer patients on endocrine therapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Estriol
  • Sponsor:Universitair Ziekenhuis Gent

Head and neck cancer

Not recruiting

Study of Monalizumab and Cetuximab for Patients with Recurrent or Metastatic Head and Neck Cancer Previously Treated with an Immune Checkpoint Inhibitor

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:AstraZeneca AB

Prostate cancer

Not recruiting

Study on Prostate Cancer Treatment: Comparing Goserelin Acetate, Leuprorelin Acetate, Degarelix, and Apalutamide in Patients with Biochemical Progression After Surgery

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Ziekenhuis Aan De Stroom

Colorectal cancer metastatic

Not recruiting

Study on EO4010 Vaccine with Nivolumab and Bevacizumab for Patients with Metastatic Colorectal Cancer Who Have Already Received Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Enterome

Bladder cancer

Not recruiting

Study on the Effectiveness of Durvalumab, Tremelimumab, and Chemotherapy in Patients with Advanced Bladder or Urinary System Cancer

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Plasma cell myeloma

Not recruiting

Study Comparing Daratumumab with Drug Combination for Young Patients with Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplantation

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years
  • Substances:Bortezomib
  • Sponsor:Ceska Myelomova Skupina z.s.

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab467 clinical trialsCarboplatin344 clinical trialsCisplatin288 clinical trialsPaclitaxel266 clinical trialsFluorouracil239 clinical trialsOxaliplatin230 clinical trialsNivolumab218 clinical trialsDexamethasone169 clinical trialsDurvalumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.